Navigation Links
Biomarker Challenges in Biosimilar Drug Development, New Life Science Webinar Hosted by Xtalks
Date:10/29/2013

Toronto, Canada (PRWEB) October 29, 2013

Biologics have transformed the way several diseases have been traditionally treated and managed over the past several years. Therapeutic antibodies are a class of biologics that has been exceptionally effective in the treatment of life threatening diseases such as cancer and inflammatory diseases.

As patents and exclusivity on several originator biologics are expiring, the industry has been moving in to generate biosimilars. Biosimilars are products that are highly similar to the originator molecules with no clinically meaningful differences in safety, purity and potency.

Owing to the complexity of biological molecules and the variability of sophisticated modern processes by which they are generated, it is extremely difficult to generate fully identical biosimilars. Subtle structural and functional differences can lead to potentially serious consequences when administered into the diseased host. Regulatory agencies require the generation of physicochemical, structural and functional data on candidate biosimilars prior to approval for use in human subjects. Thus, successful development of biosimilars requires the demonstration of pharmacological similarity with the originator biologics.

This webinar focuses on Covance's experience with in vitro assays to demonstrate pharmacological similarity between biologics and biosimilars.

A Q&A with the audience will follow the main presentation.

For more information about this event or to register, visit http://xtalks.com/biomarkers-biosimilar-drug-development.ashx.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/10/prweb11267149.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biomarkers Market to Grow at a CAGR of 18.5% to 2018 in a New Research Report at RnRMarketResearch.com
2. LC/MS Biomarker Assay Validation Strategies Using Surrogate Matrix and Surrogate Analyte Approaches, New Life Science Webinar Hosted by Xtalks
3. Biomarkers Market worth $40.8 Billion by 2018
4. Meso Scale Discovery Launches V-PLEX™ Multiplex Biomarker Immunoassays
5. Biomarkers: Technological and Commercial Outlook 2013-2023
6. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
7. Optimizing Assays from FFPE for Biomarker Strategies, New Life Science Webinar Hosted by Xtalks
8. Biomarkers predict time to ovarian cancer recurrence
9. Epigenetic and MicroRNA Biomarkers 2013 Market Report
10. Biomarkers - Technologies, Markets and Companies - Updated 2012 Report
11. Molecular Biomarkers for Cancer Detection and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
Breaking Biology Technology:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):